Prospective assessment of incidence of Tako-Tsubo cardiomyopathy in a very large urban agglomeration

International progress and evaluation on interactive coupling effects between urbanization and the eco-environment

“…To date, they argue, humanity has already overstepped three of the nine thresholds, namely, climate change, biodiversity loss and interference with the nitrogen cycle (Rockström et al, 2009). A study by Mansencal et al (2013) suggested that environmental changes in urban agglomerations can trigger greater incidence of diseases, and showed that the incidence of Tako-Tsubo cardiomyopathy is high in women over 60 in urban agglomerations in Europe, the US and Japan. Chowdhuri et al (2011) assessed the earthquake risk in and around the Agartala urban agglomeration using digital microearthquake recorders for site response studies.…”

Takotsubo cardiomyopathy and its relevance to anesthesiology: a narrative review

“…5,14,27,28,[39][40][41][42][43] Although many patients recover without complications, about 50% experience some complications. 5 Serious complications are not uncommon and include congestive heart failure (12-45%), pulmonary edema (8 to [ 20%), and cardiogenic shock (4-20%).…”

Incidence of Tako-Tsubo cardiomyopathy in urban agglomerations

“…Its incidence was uncertain and in a recent article published in the Journal [7], we have demonstrated that the annual incidence of TTC is estimated to be 29.8 per 1,000,000 inhabitants (95% CI: 18.6-44.9), 48.2 per 1,000,000 inhabitants (95% CI: 29.7-73.0) among women and 187.4 per 1,000,000 inhabitants (95% CI: 103.3-307.2) among women ≥60 years. This prospective multicentric study was conducted in Paris and its suburbs.…”

“…Based on potential antiarrhythmic effects and potential antiarrhythmic effect, a role of fish oil in the prevention of AF has been postulated. However, the results from clinical studies have been conflicting, with some showing promising conclusions [6,9] and others yielding neutral results [3][4][5]7,8,10], and a definite role of fish oil in the setting of AF has not been demonstrated. Hence, we conducted a metaanalysis to evaluate the efficacy and safety of supplementation fish oil for the prevention of recurrent AF.…”

“…Three open label studies are with lower quality (Jadad scores b3) [3,7,9], while the remaining five studies are with good quality (Jadad scores ≥3). When the three studies with lower quality were excluded, in the subgroup of administering fish oil less than 4 weeks prior to cardioversion, the risk of recurrent AF was still significantly higher than control (OR: 1.32; 95% CI 1.06 to 1.65, P = 0.02), the test for heterogeneity (I 2 = 0%, P = 0.97) (Fig.…”